Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients

Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement (TAVR) compared to other age groups, especially in regards to stroke risk, and in regards to the composite of death, stroke, and heart failure hospitalization. The late-breaking results were presented today at the Society for Cardiovascular Angiogra…

SCAI 2025: Early TAVI “should be preferred to clinical surveillance in all age groups” - Cardiovascular News

Analysis from the EARLY TAVR trial, presented at the 2025 Society for Cardiovascular Angiography & Interventions (SCAI) scientific sessions (1–3 May, Washington, DC, USA), has shown that patients between the ages of 65 and 70 years old derived the most benefits from a strategy of early intervention with transcatheter aortic valve implantation (TAVI) compared to other age groups, especially in regards to stroke risk, and in regards to the composi…

EARLY TAVR Analysis Measures Influence of Patient Age on Outcomes - Cardiac Interventions Today

May 2, 2025—Society for Cardiovascular Angiography & Interventions (SCAI) announced that an analysis from the EARLY TAVR trial showed patients aged 65 to 70 years derived the most benefits from a strategy of early intervention with transcatheter aortic valve replacement (TAVR) compared to other age groups—especially in terms of stroke risk and the composite of death, stroke, and heart failure (HF) hospitalization. The late-breaking data were pre…